Peptide News Digest

Amylyx LUCIDITY Hit: Avexitide 55% Reduction, Aizen AI Oral Peptide $100M/Target, LEO Buys Dersimelagon, Retatrutide Q1 2027

Amylyx avexitide LUCIDITY hit primary endpoint: 55% hypoglycemic reduction, p<0.001. NDA by end 2026. Aizen $100M AI oral peptide deal. LEO buys dersimelagon.

4 stories · Covering clinical-trials, industry

Editor's Note

Tuesday's peptide news is anchored on the Amylyx Pharmaceuticals (NASDAQ: AMLX) Phase 3 LUCIDITY trial hit for avexitide (exendin 9-39, a peptide GLP-1 receptor antagonist) in post-bariatric hypoglycemia announced Monday August 18. Trial results: 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003), with all secondary endpoints met including reductions in Level 2 by self-monitored blood glucose, Level 2 by continuous glucose monitoring (CGM), and Level 3 hypoglycemic events. Amylyx plans to submit a New Drug Application (NDA) to the FDA by end of 2026 with potential commercial launch of avexitide in 2027 if approved; the indication has no currently approved drug therapy. Three additional stories round out the day. Aizen Therapeutics announced a multi-program collaboration with a San Diego-based public biotech to design oral peptide therapeutics using its DaX foundation model, providing Aizen several million dollars in initial revenue and up to $100 million per nominated target across immunology and neurology indications. LEO Pharma announced Tuesday August 18 the acquisition of worldwide rights to dersimelagon (a selective melanocortin-1 receptor agonist for erythropoietic protoporphyria and X-linked erythropoietic protoporphyria) from Japanese drugmaker Mitsubishi Tanabe Pharma, extending the melanocortin therapeutic franchise landscape alongside Rhythm Pharmaceuticals' IMCIVREE (setmelanotide, MC4R) and Clinuvel's Scenesse (afamelanotide, alpha-MSH). And Eli Lilly clarified that retatrutide FDA filing was pushed from end-2026 to Q1 2027 as the company continues gathering manufacturing and quality control data.

Clinical Trials

Amylyx Pharmaceuticals (NASDAQ: AMLX) Announced Monday Evening August 18, 2026 That the Registrational Phase 3 LUCIDITY Clinical Trial of Avexitide (Exendin 9-39, a Peptide GLP-1 Receptor Antagonist Administered as 90 mg Once-Daily Subcutaneous Injection) in Post-Bariatric Hypoglycemia (PBH) Met the FDA-Agreed-Upon Primary Endpoint With a 55% Reduction in the Composite Rate of Level 2 and Level 3 Hypoglycemic Events Versus Placebo (P=0.000003); The Trial Also Met All Secondary Endpoints Including Reductions in Level 2 Events by Self-Monitoring of Blood Glucose (SMBG), Level 2 Events by Continuous Glucose Monitoring (CGM), and Level 3 Hypoglycemic Events; Avexitide Was Generally Well-Tolerated With a Favorable Safety Profile; Amylyx Plans to Submit a New Drug Application (NDA) to the FDA by End of 2026 With Potential Commercial Launch in 2027 if Approved; If Approved, Avexitide Would Be the First FDA-Approved Therapy for Post-Bariatric Hypoglycemia and the First Phase 3 Success for a GLP-1 Receptor Antagonist Mechanism

Amylyx Pharmaceuticals (NASDAQ: AMLX) announced Monday evening August 18, 2026 that the registrational Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia (PBH) met the FDA-agreed-upon primary endpoint with a 55% reduction in the composite rate of Level 2 (blood glucose < 54 mg/dL) and Level 3 (severe cognitive impairment requiring external assistance) hypoglycemic events versus placebo (p=0.000003). The trial enrolled 78 participants with PBH following Roux-en-Y gastric bypass surgery, randomized 3:2 to avexitide 90 mg once-daily subcutaneous injection or placebo for 16 weeks across 21 US sites. All secondary endpoints were met: consistent, highly statistically significant, and clinically substantial reductions in Level 2 events by self-monitoring of blood glucose (SMBG), Level 2 events by continuous glucose monitoring (CGM), and Level 3 hypoglycemic events. Avexitide was generally well-tolerated with a favorable safety profile. Mechanism: avexitide is exendin (9-39), a 30-amino-acid peptide that binds the GLP-1 receptor without activating it, blocking excessive endogenous GLP-1 signaling that drives postprandial hypoglycemia in the reconfigured gastrointestinal anatomy after Roux-en-Y gastric bypass. Amylyx plans to submit a New Drug Application (NDA) to the FDA by end of 2026 with potential commercial launch in 2027 if approved. If approved, avexitide would be the first FDA-approved therapy for post-bariatric hypoglycemia (which has no currently approved drug therapy) and the first Phase 3 success for a GLP-1 receptor antagonist mechanism (the mechanistic opposite of the semaglutide/tirzepatide agonist class).

#amylyx-pharmaceuticals #amlx #avexitide #exendin-9-39 #glp-1-receptor-antagonist #post-bariatric-hypoglycemia #lucidity #phase-3-hit #primary-endpoint-met #55-percent-reduction #first-in-class #nda-2026 #commercial-launch-2027 #roux-en-y-gastric-bypass
Industry

Aizen Therapeutics Announced a Multi-Program Collaboration With a San Diego-Based Public Biotech to Design Oral Peptide Therapeutics Using Its DaX Foundation Model, Providing Aizen With Several Million Dollars in Initial Revenue and Up to $100 Million in Milestones for Each Nominated Target Across Immunology and Neurology Indications; The DaX Platform Has Been Trained on Millions of Uniquely Annotated Molecules and Receptors and Explores the Non-Canonical Amino Acid (ncAA) Peptide Chemical Space at 10x the Scale of Traditional ncAA Discovery Methods, Positioning It as One of the More Substantial AI-Driven Peptide Discovery Platforms Alongside PeptiDream's PDPS System, Isomorphic Labs, and Insilico Medicine's Pharma.AI

Aizen Therapeutics announced a multi-program collaboration with a San Diego-based public biotech to design oral peptide therapeutics using its DaX foundation model. Deal terms: several million dollars in initial revenue plus up to $100 million in milestones for each nominated target. The collaboration will develop proof of activity with the DaX platform for well-known disease-relevant targets in immunology and neurology indications, with the potential to expand the roster of targets over time. The DaX platform has been trained on millions of uniquely annotated molecules and receptors and explores the non-canonical amino acid (ncAA) peptide chemical space at 10x the scale of traditional ncAA discovery methods. Non-canonical amino acids extend beyond the standard 20 natural amino acids to include modified building blocks that give peptides properties (metabolic stability, membrane permeability, oral bioavailability) that natural peptides do not have; this is essential for the oral peptide therapeutics that the collaboration targets. DaX positions Aizen as one of the more substantial AI-driven peptide discovery platforms alongside PeptiDream's PDPS system (Kawasaki-based, constrained cyclic peptide focus with active collaborations across Novartis, Merck, Genentech, AbbVie, and Eli Lilly), Isomorphic Labs (Google DeepMind spinout with AlphaFold-derived structural modeling), and Insilico Medicine's Pharma.AI (which has secured over $5 billion in partnership deal value across 2026). The collaboration adds to the growing evidence that AI-designed peptides are becoming a distinct drug discovery category with real deal-flow.

#aizen-therapeutics #dax-foundation-model #ai-designed-peptides #oral-peptide-therapeutics #non-canonical-amino-acid #ncaa #100-million-per-target #immunology #neurology #peptidream #isomorphic-labs #insilico-medicine #ai-drug-discovery
Industry

LEO Pharma Announced Tuesday August 18, 2026 an Agreement to Acquire Worldwide Rights to Dersimelagon (Formerly MT-7117), a Selective Melanocortin-1 Receptor (MC1R) Agonist Small-Molecule Compound Being Developed for Erythropoietic Protoporphyria (EPP) and X-Linked Erythropoietic Protoporphyria (XLEPP), From Japanese Drugmaker Mitsubishi Tanabe Pharma; Dersimelagon Is Currently in Phase 3 Trials Across Multiple Rare Photodermatoses Indications and Represents an Oral Alternative to the Currently-Approved Injectable Melanocortin-Axis Therapies Including Clinuvel's Scenesse (Afamelanotide, an Alpha-MSH Analog Peptide for EPP) and Rhythm Pharmaceuticals' IMCIVREE (Setmelanotide, an MC4R Agonist Peptide for Rare Genetic Obesity Syndromes and Acquired Hypothalamic Obesity)

LEO Pharma announced Tuesday August 18, 2026 an agreement to acquire worldwide rights to dersimelagon (formerly MT-7117) from Japanese drugmaker Mitsubishi Tanabe Pharma. Dersimelagon is a selective melanocortin-1 receptor (MC1R) agonist small-molecule compound being developed for erythropoietic protoporphyria (EPP) and X-linked erythropoietic protoporphyria (XLEPP), rare inherited photodermatoses in which patients develop severe skin pain and burning after light exposure. Dersimelagon is currently in Phase 3 trials across multiple rare photodermatoses indications. The mechanism: MC1R agonism stimulates skin cells (melanocytes) to produce more melanin, which absorbs light and reduces the pain-generating reaction to sun exposure that characterizes EPP. Dersimelagon represents an oral small-molecule alternative to the currently-approved injectable melanocortin-axis therapies including Clinuvel's Scenesse (afamelanotide, an alpha-MSH analog peptide administered as a subcutaneous implant for EPP, approved US 2019) and adjacent to Rhythm Pharmaceuticals' IMCIVREE (setmelanotide, an MC4R agonist peptide for rare genetic obesity syndromes and acquired hypothalamic obesity, approved US 2020 with the acquired hypothalamic obesity extension approved June 2026). The LEO Pharma acquisition extends the melanocortin therapeutic franchise landscape and positions LEO for a broader dermatology and rare-disease portfolio alongside its existing psoriasis and atopic dermatitis commercial franchises. Financial terms were not fully disclosed. The transaction adds to the growing melanocortin-axis drug development activity across peptide (afamelanotide, setmelanotide, melanotan II) and small-molecule (dersimelagon) modalities.

#leo-pharma #dersimelagon #mt-7117 #mitsubishi-tanabe #mc1r-agonist #erythropoietic-protoporphyria #epp #xlepp #melanocortin-axis #afamelanotide #scenesse #setmelanotide #imcivree #melanotan-ii #photodermatosis
Clinical Trials

Eli Lilly (NYSE: LLY) Clarified That the Retatrutide Regulatory Submission Timeline Was Pushed From End-2026 to Q1 2027 as the Company Continues Gathering Manufacturing and Quality Control Data Required for the FDA Biologics License Application; The TRIUMPH-1 Phase 3 Trial Readout Updated Documented 28.3% Mean Weight Loss at 80 Weeks on the 12 mg Weekly Injection Arm in 2,339 Participants With Obesity Without Type 2 Diabetes, the Largest Weight-Loss Figure Reported in Any Phase 3 Obesity Trial to Date; Combined With TRIUMPH-2 (Obesity Plus T2D at Up to 20.8% Weight Loss and 1.6 pp HbA1c Reduction in 1,152 Participants), TRIUMPH-3 (Additional Confirmatory Data), and TRIUMPH-4 (Obesity Plus Knee Osteoarthritis at 28.7% Weight Loss and 75.8% WOMAC Pain Reduction), the Retatrutide Package Now Anchors Four Major Indication Frames With Additional TRIUMPH Readouts (Obstructive Sleep Apnea, Chronic Lower Back Pain, Cardio-Renal-Metabolic Outcomes) Expected Across 2026

Eli Lilly (NYSE: LLY) clarified that the retatrutide (once-weekly injectable GIP/GLP-1/glucagon triple agonist peptide) regulatory submission timeline was pushed from end-2026 to Q1 2027 as the company continues gathering manufacturing and quality control data required for the FDA Biologics License Application. TRIUMPH-1 (obesity without type 2 diabetes) Phase 3 readout updated documented 28.3% mean weight loss at 80 weeks on the 12 mg weekly injection arm in 2,339 participants, the largest weight-loss figure reported in any Phase 3 obesity trial to date. Combined with TRIUMPH-2 (obesity plus type 2 diabetes at up to 20.8% weight loss and 1.6 percentage point HbA1c reduction in 1,152 participants), TRIUMPH-3 (additional confirmatory data), and TRIUMPH-4 (obesity plus knee osteoarthritis at 28.7% weight loss and 75.8% WOMAC pain reduction), the retatrutide package now anchors four major indication frames. Additional TRIUMPH readouts expected across 2026 in obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes will strengthen the label breadth. The Q1 2027 filing timeline shift is a modest delay from prior end-2026 signaling but reflects manufacturing-scale challenges typical of peptide APIs at the projected multi-billion-dollar commercial demand level (semaglutide and tirzepatide combined are already at roughly $80 billion annual revenue). Potential FDA approval expected in 2027 to 2028 following the standard 10-month review or 6-month priority review if a Priority Review Voucher (PRV) is deployed. Retatrutide will likely reshape the entire obesity drug class ceiling on the injectable side once approved.

#eli-lilly #lly #retatrutide #triple-agonist #triumph-1 #triumph-2 #triumph-3 #triumph-4 #bla-q1-2027 #28-3-percent-weight-loss #80-weeks #2339-participants #manufacturing-cmc